(Q50776745)

19 March 2018

title

VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. (English)

1 reference

19 March 2018

author

Freda K. Stevenson

5

1 reference

19 March 2018

author name string

Stuart D Perkins

1

1 reference

19 March 2018

M Gill Hartley

2

1 reference

19 March 2018

Roman A Lukaszewski

3

1 reference

19 March 2018

Robert J Phillpotts

4

1 reference

19 March 2018

Alice M Bennett

6

1 reference

19 March 2018

language of work or name

English

0 references

publication date

1 March 2005

1 reference

19 March 2018

published in

Vaccine

1 reference

19 March 2018

volume

23

1 reference

19 March 2018

issue

16

1 reference

19 March 2018

page(s)

1931-1940

1 reference

19 March 2018

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

1 reference

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Efficient vaccination by intradermal or intramuscular inoculation of plasmid DNA expressing hepatitis B surface antigen under desmin promoter/enhancer control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Long-term expression of a fluorescent reporter gene via direct injection of plasmid vector into mouse skeletal muscle: comparison of human creatine kinase and CMV promoter expression levels in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Liposome/DNA complexes coated with biodegradable PLA improve immune responses to plasmid encoding hepatitis B surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Electroporation improves the efficacy of DNA vaccines in large animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

DNA fusion vaccines against B-cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Intercellular trafficking and protein delivery by a herpesvirus structural protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Intercellular delivery of functional p53 by the herpesvirus protein VP22.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Gene transfer into the central nervous system in vivo using a recombinanat lentivirus vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Direct protein transfer to terminally differentiated muscle cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

A novel approach to induce cell cycle reentry in terminally differentiated muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Genetic engineering of the glucocorticoid receptor by fusion with the herpes viral protein VP22 causes selective loss of transactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Is VP22 nuclear homing an artifact?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Intercellular trafficking of VP22-GFP fusion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Protein delivery using VP22.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

A genetic immunization adjuvant system based on BVP22-antigen fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Conformational lability of herpesvirus protein VP22.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

DNA vaccination protects against botulinum neurotoxin type F

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Enhancement of antibody responses to an HIV-2 DNA envelope vaccine using an expression vector containing a constitutive transport element

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

"Translocatory proteins" and "protein transduction domains": a critical analysis of their biological effects and the underlying mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Enhancing T cell activation and antiviral protection by introducing the HIV-1 protein transduction domain into a DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Cell surface adherence and endocytosis of protein transduction domains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.033

10.1016/J.VACCINE.2004.10.033

7 January 2021

Identifiers

DOI

1 reference

19 March 2018

release_pf4bv2yzs5f4bcnhd5yhz56phm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pf4bv2yzs5f4bcnhd5yhz56phm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

19 March 2018